Company Description
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin.
It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions.
In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers.
Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1989 |
| IPO Date | Aug 8, 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,200 |
| CEO | Catherine Szyman |
Contact Details
Address: 52 Discovery Irvine, California 92618 United States | |
| Phone | 949 297 7000 |
| Website | masimo.com |
Stock Details
| Ticker Symbol | MASI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0000937556 |
| CUSIP Number | 574795100 |
| ISIN Number | US5747951003 |
| Employer ID | 33-0368882 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Catherine M. Szyman | Chief Executive Officer and Director |
| Micah Young CPA | Executive Vice President and Chief Financial Officer |
| Anand Sampath | Executive Vice President of Operations |
| Paul Hataishi | Senior Vice President and Chief Accounting Officer |
| Yongsam Lee | Executive Vice President and Chief Information Officer |
| Dr. Steven J. Barker | Chairman of Scientific Advisory Board and Chief Science Officer |
| Matthew Brinckman | Senior Vice President of FP&A and Investor Relations |
| Charles Dadswell | Executive Vice President and General Counsel |
| Tim A. Benner | Chief Marketing and Strategy Officer |
| Elisabeth A. Hellmann | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | SCHEDULE 13G/A | Filing |
| Feb 27, 2026 | DFAN14A | Filing |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | DFAN14A | Filing |
| Feb 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |